Page 24 - The DHEA Debate - Life Extensions Magazine

95. Schatzl G, Reiter WJ, Thurridl T, et al. Endocrine patterns in patients with benign and
malignant prostatic diseases. Prostate. 2000 Aug;44(3):219-24.
96. Huot RI, Shain SA. Differential metabolism of dehydroepiandrosterone sulfate and estrogen
conjugates by normal or malignant AXC/SSh rat prostate cells and effects of these steroid
conjugates on cancer cell proliferation in vitro. J Steroid Biochem. 1988 Jun;29(6):617-21.

97. McCormick DL, Rao KV. Chemoprevention of hormone-dependent prostate cancer in the
Wistar- Unilever rat. Eur Urol. 1999 May;35(5- 6):464-7.

98. Ponholzer A, Plas E, Schatzl G, Jungwirth A, Maderbacher S. Association of DHEA- S and
estradiol serum levels to symptoms of aging men. Aging Male. 2002 Dec; 5(4):233-8.

99. Sun Y, Mao M, Sun L, Feng Y, Yang J, Shen P. Treatment of osteoporosis in men using
dehydroepiandrosterone sulfate. Chin Med J. (Engl) 2002; 115(3):402-4.
100. Wallace MB, Lim J, Cutler A, Bucci L. Effects of dehydroepiandrosterone vs
androstenedione supplementation in men. Med Sci Sports Exerc. 1999 Dec; 31(12):1788-92.
101. Miyamoto H, Marwah P, Marwah A, Lardy H, Chang C. 3 beta-acetoxyandrost- 1,5-diene-
17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proc Natl
Acad Sci (USA). 2003 Apr 15; 100(8):4440-4.

102. Greenwald P. Cancer risk factors for selecting cohorts for large scale chemo prevention
trials. J Cell Biochem Suppl. 1996;25:29-36.

103. Reiter WJ, Schatzl G, Zeiner A, Pycha A, Merberger M. Dehydroepiandrosterone in the
treatment of erectile dysfunction in patients with different organic etiologies. Urol Res. 2001
Aug; 29(4):278-81.

104. Reiter WJ, Pycha A, Schatzl G. Dehydroepiandrosterone in the treatment of erectile
dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology. 1999
Mar;53(3):590-94.
105. Steel N. Dehydroepiandrosterone and aging. Age Ageing. 1999 Mar;28(2):89-91.

106. Cutting CW, Hunt C, Nisbet JA, Bland JM, Dalgleish AG, Kirby RS. Serum insulin-like
growth factor-1 is not a useful marker of prostate cancer. BJU Int. 1999 Jun;83(9):996-9.

107. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor I: tumor marker
or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res.
2003 Jul 15; 63(14):3991-4.

108. Wan JM, Istfan NW, Ye SL, Bistrian BR. Insulin-like growth factor-1 is not mitogenic for the
Walker-256 carcinosarcoma. Life Sci. 1995 Jan 27;56(10):747-56.

109. Sonntag WE, Lynch C, Thornton P, Khan A, Bennett S, Ingram R. The effects of growth
hormone and IGF-1 deficiency on cerebrovascular and brain aging. J Anat.2000 Nov;197 Pt
4:575-85.
110. Haden ST, Glowacki J, Hurwitz S, Rosen C, LeBoff MS. Effects of age on serum
dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women. Calcif Tissue Int. 2000
Jun;66(6):414-8.
111. Ravaglia G, Forti P, Maioli F, et al. Body composition, sex steroids, IGF-1, and bone
mineral status in aging men. J Gerontol A Biol Sci Med Sci. 2000 Sep;55(9):M516-21.